The Journal of Practical Medicine >

2024 , Vol. 40 >Issue 12: 1659 - 1664

DOI: https://doi.org/10.3969/j.issn.1006-5725.2024.12.008

Clinical Research

Reduction of head and neck lymphedema by placing dose limiting rings in the anterior and posterior regions of the neck for treating early nasopharyngeal carcinoma using intensity-modulated radiotherapy： A dosimetric perspective

  • Kai LIAO ,
  • Yunhong TIAN ,
  • Ronghui ZHENG ,
  • Caixian HE ,
  • Jiyong PENG ,
  • Huijun LI
Expand
  • Department of Radiotherapy，Cancer Hospital，Guangzhou Medical University，Guangzhou 510095，China

Received date: 2023-09-27

  Online published: 2024-06-14

Fold

Abstract

Objective To establish an optimal limiting dose for dose limiting rings placed in the anterior and posterior regions of the neck for reducing head and neck lymphedema under intensity-modulated radiation therapy（IMRT） for early nasopharyngeal carcinoma（NPC） from a dosimetric perspective. Method Fifteen newly diagnosed early-stage nasopharyngeal carcinoma patients who underwent CT localization for radiotherapy at the Cancer Hospital of Guangzhou Medical University from January to September 2022 were included in the study. Each case was designed with five sets of radiotherapy plans. Plan A consisted of conventional unlimited-field plans， while Plans B-E consisted of limited-field plans with dose constraints set at 20， 18， 16， and 14 Gy， respectively， with the remaining parameters consistent with Plan A. The impact on target coverage and organ-at-risk constraints was evaluated through variance analysis and pairwise multiple comparisons using a randomized block design to determine the optimal dose limits. Results The gradient of 16Gy was determined as the optimal dose limiting cutoff point for achieving the balance between target coverage and organ limiting dose. Compared with the conventional plan， The plans with the placement of a cervical anterior and posterior dose limiting ring （16Gy） did not change the target dose coverage （P > 0.05）， but only yielded a slight change in the homogeneity index （P < 0.05）. It did not cause any changes of the dosage in the inner ear， mandible， and brainstem （all P > 0.05）， but lead to statistically significant reductions in the oral cavity， throat， and thyroid （all P < 0.05）. It caused a slight increase of the dose in the parotid gland and spinal cord （both P < 0.05）， but the increased dose was anyhow within the tolerance range. Conclusion The dosimetric investigation determines an optimal dose limit cutoff point for the cervical anterior and posterior dose limiting rings. It is expected to provide a design method for IMRT plans to reduce head and neck lymphedema after radiotherapy for early NPC.

Key words： nasopharyngeal carcinoma; IMRT; lymphedema; dosimetry

Cite this article

Kai LIAO , Yunhong TIAN , Ronghui ZHENG , Caixian HE , Jiyong PENG , Huijun LI . Reduction of head and neck lymphedema by placing dose limiting rings in the anterior and posterior regions of the neck for treating early nasopharyngeal carcinoma using intensity-modulated radiotherapy： A dosimetric perspective[J]. The Journal of Practical Medicine, 2024 , 40(12) : 1659 -1664 . DOI: 10.3969/j.issn.1006-5725.2024.12.008

References

1 方楠，张俊安，孙俊旗，等. 鼻咽癌原发肿瘤MRI-DWI联合体积预测鼻咽部放化疗近期疗效［J］. 实用医学杂志， 2021，37（8）：1037-1040+1045.
2 ZHENG L， TONG L， DU F，et al. Effect of three-dimensional conformal radiotherapy and intensity-modulated radiotherapy on parotid gland function and quality of life in patients with nasopharyngeal carcinoma［J］. Am J Transl Res， 2021，13（5）：5272-5279.
3 刘慧，何彩娴，彭继勇，等. 鼻咽癌放射治疗致放射性颈动脉损伤的研究进展［J］. 实用医学杂志， 2023，39（10）：1201-1205. doi:10.3969/j.issn.1006-5725.2023.10.002
4 YANG S S， PANG Y J， WANG Z Q，et al. Development and prospective validation of a risk score model in guiding individualized concurrent chemoradiotherapy in stage II nasopharyngeal carcinoma in intensity-modulated radiotherapy era［J］. Cancer Med， 2022，11（4）：1109-1118. doi:10.1002/cam4.4520
5 LIANG Y J， LIU L T， LI Y，et al. Association of treatment advances with survival rates in pediatric patients with nasopharyngeal carcinoma in China，1989-2020［J］. JAMA Netw Open，2022，5（3）：e220173. doi:10.1001/jamanetworkopen.2022.0173
6 ROSENTHAL D I， CHAMBERS M S， FULLER C D，et al. Beam path toxicities to non-target structures during intensity modulated radiation therapy for head and neck cancer［J］. Int J Radiat Oncol Biol Phys， 2008，72（3）：747-755. doi:10.1016/j.ijrobp.2008.01.012
7 KIM D，NAM J， KIM W，et al. Radiotherapy dose-volume parameters predict facial lymphedema after concurrent chemoradiation for nasopharyngeal carcinoma［J］. Radiat Oncol， 2021，16（1）：172. doi:10.1186/s13014-021-01901-7
8 KALEMIKERAKIS I， EVAGGELAKOU A， KAVGA A，et al. Diagnosis，treatment and quality of life in patients with cancer-related lymphedema［J］. J BUON， 2021， 26（5）：1735-1741.
9 黄娟，陈晓慧，翟瑞萍，等. 鼻咽癌调强放射治疗设置头颈前部淋巴引流保护区的剂量学可行性研究［J］. 中国癌症杂志，2018，28（9）：692-697.
10 廖恺，冯建辉，谭锦云，等. 鼻咽癌调强放疗后头颈淋巴水肿的危险因素分析［J］. 实用肿瘤杂志， 2021，36（2）：124-128.
11 LEE A W， NG W T， PAN J J，et al. International guideline for the delineation of the clinical target volumes（CTV） for nasopharyngeal carcinoma［J］. Radiother Oncol， 2018，126（1）：25-36. doi:10.1016/j.radonc.2017.10.032
12 TANG LL， HUANG C L， ZHANG N，et al. Elective upper-neck versus whole-neck irradiation of the uninvolved neck in patients with nasopharyngeal carcinoma： an open-label， non-inferiority， multicentre， randomised phase 3 trial［J］. Lancet Oncol， 2022，23（4）：479-490. doi:10.1016/s1470-2045(22)00058-4
13 中国鼻咽癌临床分期工作委员会. 2010鼻咽癌调强放疗靶区及剂量设计指引专家共识［J］. 中华放射肿瘤学杂志， 2011，20（4）：267-269. doi:10.3760/cma.j.issn.1004-4221.2011.04.001
14 LEE A W， NG W T， PAN J J， et al. International guideline on dose prioritization and acceptancecriteria in radiation therapy planning for nasopharyngeal carcinoma［J］. Int J Radiat Oncol Biol Phys， 2019，105（3）：567-580. doi:10.1016/j.ijrobp.2019.09.030
15 CHEN D， CAI S B， SOON Y Y， et al. Dosimetric comparison between Intensity Modulated Radiation Therapy（IMRT） vs dual arc Volumetric Arc Therapy（VMAT） for nasopharyngeal cancer（NPC）：Systematic review and meta-analysis［J］. J Med Imaging Radiat Sci， 2023，54（1）：167-177. doi:10.1016/j.jmir.2022.10.195
16 AKBAS U， KOKSAL C， KESEN N D，et al. Nasopharyngeal carcinoma radiotherapy with hybrid technique［J］. Med Dosim， 2019，44（3）：251-257. doi:10.1016/j.meddos.2018.09.003
17 FADHIL M， SINGH R， HACAS T， et al. Systematic review of head and neck lymphedema assessment ［J］. Head Neck， 2022， 44（10）： 2301-2315. doi:10.1002/hed.27136
18 PIGOTT A， NIXON J， FLEMING J，et al. Head and neck lymphedema management： Evaluation of a therapy program［J］. Head Neck， 2018，40（6）：1131-1137. doi:10.1002/hed.25086
19 SANGUINETI G， ADAPALA P， ENDRES E J，et al. Dosimetric predictors of laryngeal edema［J］. Int J Radiat Oncol Biol Phys，2007，68（3）：741-749. doi:10.1016/j.ijrobp.2007.01.010
20 KINRPAMCK J P， VAN DER KOGEL A J， SEHULTHEISS T E.Radiation dose-volume effects in the spinal cord［J］. Int J Radiat Oncol Biol Phys， 2010，76（）：42-49. doi:10.1016/j.ijrobp.2009.04.095
21 JEANS C， BROWN B， WARD E C，et al. Lymphoedema after head and neck cancer treatment：an overview for clinical practice［J］. Br J Community Nurs， 2021， 26（Sup4）：S24-S29. doi:10.12968/bjcn.2021.26.sup4.s24
Options
Outlines

/

〈 〉